摘要
【目的】利用microRNA芯片技术分析比较两组不同复发倾向肝癌患者的miRNA表达谱,并在更大样品的基础上进行实验验证。【方法】收集10例原发性肝癌组织标本根据术后复发情况分2组:早期复发组与非早期复发组,运用microRNA芯片技术筛选出差异表达显著的microRNAs。结合文献报道,选择mir-144、mir-502-3p作为其他82例肝癌组织标本qReal-time PCR验证的检测指标。并利用生物信息学方法预测其靶基因。【结果】本研究共筛选获得7个差异表达的microRNAs。与非早期复发组相比,在早期复发组中有4个表达上调,3个表达下调。qReal-time PCR验证与microRNA芯片筛选的结果一致。生物信息学方法预测miR-144靶基因可能为Rb1,miR-502-3p靶基因可能为SET。【结论】microRNA芯片筛选的mir-144、mir-451、mir-486-5p、mir-602、mir-551b、mir-96、mir-502-3p与原发性肝癌术后早期复发密切相关。
[ Objective ] To select effectiveness of microRNAs and correlated with early recurrence after radical surgery in liver cancer by microRNA profiling, which analyzing verified the results by tissue samples on the basis. [Methods] 10 HCC cases with radical surgery were divided into 2 group： early recurrence group and non-early recurrence group, according to postoperative recurrence in primary hepatocellular carcinoma. MicroRNA profiling study were performed to obtain some different and significant microRNAs. According to literature, mir-144 and mir-502-3p were used to detect HCC recurrence by real-time PCR with 82 HCC cases, and target genes were predicted using bioinformatics. [ Results] Expression of 7 miRNAs were different and significant in the HCC with early recurrence group. Comparing with non-early recurrrence group, 4 miRNAs were up-regulated in early recurrence group. However, 3 miRNAs were down-regulated. The result of mir-144 and mir-502-3p expression by real-time PCR was uniformity to microarray. Rbl might be a potential target gene of mir-144; SET might be a potential target gene of mir-502-3p. [Conclusions] Mir-144, mir-451, mir-486-Sp, mir-602, mir-551b, mir-96, and mir-502-3p were correlated with early recurrence after radical surgery in primary hepatocellular carcinoma with analyzing and screening of microRNA profile by microarray.
出处
《中山大学学报（医学科学版）》
CAS
CSCD
北大核心
2012年第4期494-498,共5页
Journal of Sun Yat-Sen University:Medical Sciences
基金
广东省科技计划项目(2009B080701021
2010B080701021)
广东省医学科研基金(A2010002)
广东省自然科学基金(10151008004000002)
作者简介
邓治亮，硕士研究生，研究方向：肝癌的综合治疗。
通信作者：孙建，副主任医师，E—mail：akeyman@yahoo．com．cn
